Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or...
Brain
WorkFar Robotics Unleashes Sentient Humanoid Robots “Syntro” into the WorkForce
WorkFar Robotics' sentient humanoid "Syntro" is a sophisticated, AI-enhanced robot in human form that can be effortlessly controlled by a...
MEDFAR, Fastest-growing EMR/EHR Provider, Announces Successful Entry Into the U.S. Primary Care Market with COMTRON Integration
MEDFAR Unveils New Brand Identity Reflecting Its Growth and Ambitious Healthcare Goals MONTREAL, Aug. 8, 2024 /PRNewswire/ - MEDFAR, developer...
Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)...
Natus introduces autoSCORE, an innovative AI solution capable of a new era of expert-level clinical EEG interpretation
MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence...
LabCentral Launches “The Dish with Johannes” Video Series Profiling Biotech Entrepreneurs and Scientists Shaping the Industry’s Future
CAMBRIDGE, Mass., Aug. 7, 2024 /PRNewswire/ -- LabCentral, the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, launched...
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) --...
Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical...
BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting
August 7, 2024News Release BioPorto A/S to Host Second Quarter 2024 Earnings Webcast & Investor Meeting COPENHAGEN, DENMARK and BOSTON, MA,...
Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic...
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food...
New Results from AlzeCure’s Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024
STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Cryoport Reports Second Quarter 2024 Financial Results
Revenue improved sequentially across all businessesCommercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total...
New Industry Report Reveals Revenue Reliability Crisis Impacting Life Sciences Companies’ Financial Performance and Ability to Meet Healthcare Needs
Survey of C-Suite leaders highlights why life sciences commercial model requires an urgent shift SAN FRANCISCO, Aug. 6, 2024 /PRNewswire/...
Luminopia Covered by Highmark Health for Treatment of Pediatric Amblyopia
Luminopia meets rigorous criteria set by Highmark's New Technology Advisory Committee (NTAC) and receives a positive coverage determination from the...
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
Figure 1 Combination of dulaglutide (Trulicity®) and buntanetap improves memory and synaptic plasticity in AD mice (*p<0.05, **p<0.01). Figure 2...
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025...
Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
On track to report preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in Q4 2024...
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024On track...